Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer.
The company serves its clients in the United States and internationally.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB PharmaS. A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.25 Increased by +7.41% | -0.20 Decreased by -25.00% |
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Mar 4, 24 | -0.22 Increased by +31.25% | -0.21 Decreased by -4.76% |
| Nov 7, 23 | -0.24 Increased by +22.58% | -0.20 Decreased by -20.00% |
| Aug 8, 23 | -0.27 Increased by +68.24% | -0.28 Increased by +3.57% |
| May 9, 23 | -0.32 Increased by +34.69% | -0.25 Decreased by -28.00% |
| Feb 28, 23 | -0.32 Increased by +59.49% | -0.45 Increased by +28.89% |
| Nov 3, 22 | -0.31 Increased by +55.71% | -0.45 Increased by +31.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 24.12 M Decreased by -0.08% | -37.06 M Increased by +19.15% | Decreased by -153.61% Increased by +19.09% |
| Jun 30, 24 | 23.49 M Increased by +14.59% | -52.36 M Decreased by -2.43% | Decreased by -222.93% Increased by +10.61% |
| Mar 31, 24 | 21.64 M Increased by +0.21% | -36.80 M Increased by +73.14% | Decreased by -170.07% Increased by +73.20% |
| Dec 31, 23 | 23.89 M Increased by +8.45% | -42.08 M Increased by +29.50% | Decreased by -176.17% Increased by +35.00% |
| Sep 30, 23 | 24.14 M Increased by +2.20% | -45.84 M Increased by +22.37% | Decreased by -189.85% Increased by +24.04% |
| Jun 30, 23 | 20.50 M Decreased by -5.03% | -51.12 M Increased by +67.86% | Decreased by -249.39% Increased by +66.16% |
| Mar 31, 23 | 21.59 M Decreased by -13.00% | -137.02 M Decreased by -51.58% | Decreased by -634.52% Decreased by -74.24% |
| Dec 31, 22 | 22.02 M Decreased by -11.94% | -59.69 M Increased by +59.02% | Decreased by -271.03% Increased by +53.46% |